Pressure Mounts in a Surging and Politicized GLP-1 Market The companys move also reflects growing market and political scrutiny
The more we look into it there are benefits like preventing recurring heart attacks, making people feel better with heart failure, he said
The trial randomised 2,339 adults with obesity (or overweight with a weight-related comorbidity) and without type 2 diabetes to retatrutide 4mg, 9mg, or 12mg weekly (titrated upward from 2mg in four-weekly steps) or placebo
Although the existing evidence in HFpEF is compelling, further trials seem warranted, particularly with respect to the effects of GLP-1 RAs on clinical outcomes and, possibly, in broader patient populations, such as patients with HFrEF or those without obesity.
Can I get GLP-1 medications with a BMI of 28
A 2023 analysis of adverse event reporting systems found no unexpected safety signals when both agents were prescribed concurrently in real-world settings